Richard Giltner Net Worth

The estimated Net Worth of Richard Giltner is at least $8.51 Milione dollars as of 13 July 2024. Mr. Giltner owns over 1,800 units of United Therapeutics Corp stock worth over $6,030,630 and over the last 16 years he sold UTHR stock worth over $2,032,376. In addition, he makes $451,256 as Independent Director at United Therapeutics Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Giltner UTHR stock SEC Form 4 insiders trading

Richard has made over 37 trades of the United Therapeutics Corp stock since 2010, according to the Form 4 filled with the SEC. Most recently he exercised 1,800 units of UTHR stock worth $623,142 on 13 July 2024.

The largest trade he's ever made was exercising 20,000 units of United Therapeutics Corp stock on 25 September 2014 worth over $620,800. On average, Richard trades about 4,141 units every 99 days since 2009. As of 13 July 2024 he still owns at least 17,420 units of United Therapeutics Corp stock.

You can see the complete history of Mr. Giltner stock trades at the bottom of the page.

Richard Giltner biography

Richard A. Giltner serves as Independent Director of the Company. From 2009 until his retirement in 2010, Mr. Giltner was a portfolio manager at Lyxor Asset Management, an asset management group at the French bank Société Générale. From 2006 until 2009, he served as a managing director of Société Générale Asset Management, an international fund management firm, and head of the European office for its fund of hedge funds group. From 2003 to 2006, Mr. Giltner was the global head of foreign exchange options for the investment banking arm of Société Générale. He also held various other managerial positions within Société Générale from 1991 until 2003. Mr. Giltner has been a private investor since his retirement from Société Générale in 2010. Our Board of Directors has determined that Mr. Giltner is an audit committee financial expert as defined under the rules and regulations of the SEC and meets the financial sophistication requirements of Nasdaq's listing standards. Mr. Giltner has served as a United Therapeutics director since 2009.

What is the salary of Richard Giltner?

As the Independent Director of United Therapeutics Corp, the total compensation of Richard Giltner at United Therapeutics Corp is $451,256. There are 12 executives at United Therapeutics Corp getting paid more, with Martine Rothblatt having the highest compensation of $15,627,500.

How old is Richard Giltner?

Richard Giltner is 56, he's been the Independent Director of United Therapeutics Corp since 2009. There are 14 older and 5 younger executives at United Therapeutics Corp. The oldest executive at United Therapeutics Corp is Louis Sullivan, 86, who is the Independent Director.

What's Richard Giltner's mailing address?

Richard's mailing address filed with the SEC is C/O UNITED THERAPEUTICS CORPORATION, 1000 SPRING STREET, SILVER SPRING, MD, 20910.

Insiders trading at United Therapeutics Corp

Over the last 20 years, insiders at United Therapeutics Corp have traded over $68,910,395 worth of United Therapeutics Corp stock and bought 229,703 units worth $13,655,671 . The most active insiders traders include Martine A Rothblatt, David Zaccardelli e Roger Jeffs. On average, United Therapeutics Corp executives and independent directors trade stock every 3 days with the average trade being worth of $2,310,818. The most recent stock trade was executed by James Edgemond on 9 September 2024, trading 8,332 units of UTHR stock currently worth $991,341.

What does United Therapeutics Corp do?

united therapeutics corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. we currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! our employees can be found collaborating across the united states, europe and asia. as a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases. #weareunitherians

Complete history of Mr. Giltner stock trades at United Therapeutics Corp

United Therapeutics Corp executives and stock owners

United Therapeutics Corp executives and other stock owners filed with the SEC include:

• Martine Rothblatt,
  Chairman of the Board, Chief Executive Officer
• Michael Benkowitz,
  President, Chief Operating Officer
• Paul Mahon,
  Executive Vice President, General Counsel, Corporate Secretary
• James Edgemond,
  Chief Financial Officer, Treasurer
• Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.,
  Founder, Chairman & CEO
• Dr. Martine A. Rothblatt,
  Founder, Chairman & CEO
• Michael I. Benkowitz,
  Pres & COO
• Paul A. Mahon,
  Exec. VP, Gen. Counsel & Corp. Sec.
• Paul A. Mahon J.D.,
  Exec. VP, Gen. Counsel & Corp. Sec.
• James C. Edgemond,
  CFO & Treasurer
• Christopher Patusky,
  Lead Independent Vice Chairman of the Board
• Christopher Causey,
  Independent Director
• Richard Giltner,
  Independent Director
• Louis Sullivan,
  Independent Director
• Tommy Thompson,
  Independent Director
• Nilda Mesa,
  Independent Director
• Judy Olian,
  Independent Director
• Katherine Klein,
  Independent Director
• Raymond Kurzweil,
  Independent Director
• Raymond Dwek,
  Independent Director
• Linda Maxwell,
  Director
• Dewey Steadman C.F.A.,
  Head of Investor Relations
• Leigh Peterson,
  VP of Product Devel.
• Gil Golden,
  Sr. VP & Chief Medical Officer
• Patrick Poisson,
  Exec. VP of Technical Operations
• Kevin T. Gray,
  Sr. VP of Strategic Operations & Logistics
• Holly Hobson,
  Associate VP of HR
• Dewey Steadman C.F.A., CFA,
  Head of Investor Relations
• Jan Malcolm,
  
• Ray Kurzweil,
  
• Roger Jeffs,
  President & COO
• Fred T Hadeed,
  EVP & CFO
• David Zaccardelli,
  EVP & Chief Operating Officer
• John Maxim Ferrari,
  CFO & Treasurer
• R Paul Gray,
  Director
• Lilly & Co Eli,
  Director, Chairman and CEO